vor 4 Jahren

DGAP-Adhoc: FYB201, Formycons Biosimilar für Lucentis® (Ranibizumab), erhält CHMP-Empfehlung der EMA

DGAP-Ad-hoc: Formycon AG / Schlagwort(e): Zulassungsgenehmigung/Zwischenbericht
FYB201, Formycons Biosimilar für Lucentis® (Ranibizumab), erhält CHMP-Empfehlung der EMA

24.06.2022 / 14:26 CET/CEST
Veröffentlichung einer Insiderinformation...

Quelle: Börse Online RSS Feed

SATOSHI - 18 years ago - "We can win a major battle.. and gain a new territory of freedom for several years."vor 6 Stunden
Jack Mallers explains why he keeps DCAing into Bitcoin, top or bottom:vor 7 Stunden
India’s first Bitcoin-backed INR lending platform is now live (pilot)vor 7 Stunden
Mr. Bitcoin someone told me you was deadvor 8 Stunden
Bought the rumor so I could sell the newsvor 8 Stunden
Can I say the "we are so back" line now?vor 8 Stunden
imagine being bullish on something majorly valued in a ish coin like the u.s. dollar that has lost over 98% of its value in the last 100 year.vor 9 Stunden
I’ve reached my second goal! 0.02 in BTCvor 9 Stunden
Can be confusingvor 10 Stunden
Don’t give us hope?vor 13 Stunden

DGAP-Adhoc: FYB201, Formycons Biosimilar f&#252;r Lucentis&#174; (Ranibizumab), erh&#228;lt CHMP-Empfehlung der EMA

DGAP-Adhoc: FYB201, Formycons Biosimilar für Lucentis® (Ranibizumab), erhält CHMP-Empfehlung der EMA